secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOCRYST PHARMACEUTICALS INC (BCRX)
CIK:        0000882796
Form:       8-K
Filed at:   2023-12-01T23:59:59+00:00
Accession:  0001171843-23-007377
Event type: leadership
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

BioCryst director Kenneth B. Lee, Jr. to retire from Board on Dec 31, 2023
--------------------------------------------------------------------------

- Lee notified company Nov 28, 2023 of retirement effective Dec 31, 2023.
- He served as Audit Committee Chair and Finance Committee member.
- Lee cited no disagreement with Board or management regarding company operations.
- Lee had been a Board member for 12 years.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/882796/000117184323007377/0001171843-23-007377-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/882796/000117184323007377/f8k_113023.htm
  HTML page:      https://secwatch.observer/filing/0001171843-23-007377

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer